PATENT CLAIM ANALYSIS

Application Number: 15778897
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "086000"]

Abstract:
The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

Claim (Index 20):
A method of inhibiting anaplastic lymphoma kinase (AKL), comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof of any one of  claim 1 , or a pharmaceutical composition of  claim 17  to patients in need thereof.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 93.0
- Lexical Diversity: 1.76596
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14652705', '15537002', '10689381', '14786069', '14391386']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7778252485661293
- 35 USC 102 Novelty (BERT): 0.5047505634114541
- Combined Prediction Score: 0.7505177800506617
- Mean Citation Score: 266.572804
- Max Citation Score: 271.7428
- Similarity Product: 197.4729843553543

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test